7-Apr-2026
Immunome (IMNM) Receives a Buy from LifeSci Capital
TipRanks (Tue, 7-Apr 7:36 AM ET)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 2-Apr 4:00 PM ET)
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
Business Wire (Tue, 3-Mar 4:02 PM ET)
Immunome to Present at Upcoming Investor Conferences
Business Wire (Mon, 23-Feb 8:00 AM ET)
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Globe Newswire (Thu, 5-Feb 9:26 AM ET)
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Business Wire (Wed, 4-Feb 8:00 AM ET)
Immunome's $400 Million Public Offering Draws Focus to Cancer Therapy Pipeline and Investor Demand
Market Chameleon (Wed, 17-Dec 2:55 AM ET)
Immunome to Reveal Pivotal Phase 3 Results for Varegacestat in Desmoid Tumors—What’s at Stake?
Market Chameleon (Mon, 15-Dec 5:28 AM ET)
Immunome’s Varegacestat Delivers Landmark Efficacy in Phase 3 RINGSIDE Trial for Desmoid Tumors
Market Chameleon (Mon, 15-Dec 2:30 AM ET)
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of April 7, 2026, IMNM stock price climbed to $21.58 with 1,123,048 million shares trading.
IMNM has a beta of 1.29, meaning it tends to be more sensitive to market movements. IMNM has a correlation of 0.15 to the broad based SPY ETF.
IMNM has a market cap of $2.38 billion. This is considered a Mid Cap stock.
Last quarter Immunome reported $0 in Revenue and -$.75 earnings per share. This fell short of revenue expectation by $-784,620 and missed earnings estimates by -$.15.
In the last 3 years, IMNM traded as high as $30.96 and as low as $4.44.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
IMNM has outperformed the market in the last year with a price return of +263.9% while the SPY ETF gained +31.9%. IMNM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.3% and +4.0%, respectively, while the SPY returned -4.5% and +0.6%, respectively.
IMNM support price is $20.64 and resistance is $22.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM shares will trade within this expected range on the day.
